Products Benralizumab was approved as a solution for injection in the United States in 2017 and in the EU and many countries in 2018 (Fasenra). Structure and properties Benralizumab is a humanized and afucosylated IgG1κ antibody with a molecular mass of 150 kDa. It is produced by biotechnological methods. Omission of the fucose in the … Benralizumab
Products Reslizumab was approved in the United States and EU in 2016 and in many countries in 2017 as a concentrate for the preparation of an infusion solution (Cinqaero). Structure and properties Reslizumab is a humanized IgG4/κ monoclonal antibody produced by biotechnological methods. The molecular mass is approximately 147 kDa. Effects Reslizumab (ATC R03DX08) binds … Reslizumab
Products Mepolizumab was approved in the US and EU in 2015 and in many countries in 2016 in the form of a solution for injection (Nucala). Structure and properties Mepolizumab is a humanized IgG1κ monoclonal antibody with a molecular mass of 149 kDa produced by biotechnological methods. Effects Mepolizumab (ATC R03DX09) has anti-inflammatory and antiasthmatic … Mepolizumab
